Equities Analysts Set Expectations for VKTX FY2027 Earnings

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Analysts at William Blair issued their FY2027 earnings per share estimates for shares of Viking Therapeutics in a research report issued on Wednesday, February 5th. William Blair analyst A. Hsieh expects that the biotechnology company will earn ($2.42) per share for the year. William Blair has a “Outperform” rating on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($0.97) per share.

Viking Therapeutics (NASDAQ:VKTX) last issued its earnings results on Wednesday, February 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same quarter in the previous year, the business earned ($0.25) EPS.

A number of other research firms have also recently weighed in on VKTX. Piper Sandler cut their price target on Viking Therapeutics from $74.00 to $71.00 and set an “overweight” rating on the stock in a research note on Thursday. HC Wainwright reiterated a “buy” rating and issued a $102.00 price objective on shares of Viking Therapeutics in a report on Thursday. B. Riley started coverage on shares of Viking Therapeutics in a research report on Friday, November 22nd. They set a “buy” rating and a $109.00 price objective for the company. StockNews.com raised shares of Viking Therapeutics to a “sell” rating in a research report on Tuesday, October 15th. Finally, Raymond James boosted their price target on shares of Viking Therapeutics from $122.00 to $125.00 and gave the company a “strong-buy” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $107.08.

Viking Therapeutics Trading Down 6.1 %

Shares of VKTX opened at $31.46 on Friday. The firm has a market capitalization of $3.51 billion, a price-to-earnings ratio of -33.83 and a beta of 0.90. The firm’s fifty day simple moving average is $40.46 and its 200-day simple moving average is $54.01. Viking Therapeutics has a twelve month low of $23.81 and a twelve month high of $99.41.

Institutional Investors Weigh In On Viking Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Blue Trust Inc. acquired a new stake in shares of Viking Therapeutics in the 3rd quarter worth approximately $26,000. GAMMA Investing LLC boosted its position in Viking Therapeutics by 124.6% during the third quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 243 shares in the last quarter. Gilliland Jeter Wealth Management LLC acquired a new stake in Viking Therapeutics in the third quarter valued at $32,000. Stone House Investment Management LLC increased its holdings in Viking Therapeutics by 66.7% during the 3rd quarter. Stone House Investment Management LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 200 shares in the last quarter. Finally, YANKCOM Partnership acquired a new position in shares of Viking Therapeutics during the 4th quarter worth approximately $33,000. 76.03% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Viking Therapeutics news, CEO Brian Lian sold 194,490 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $42.75, for a total transaction of $8,314,447.50. Following the transaction, the chief executive officer now owns 2,366,570 shares in the company, valued at approximately $101,170,867.50. The trade was a 7.59 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Marianna Mancini sold 54,215 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $42.75, for a total value of $2,317,691.25. Following the completion of the sale, the chief operating officer now directly owns 374,134 shares of the company’s stock, valued at $15,994,228.50. This represents a 12.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 299,014 shares of company stock valued at $12,782,849. 4.70% of the stock is owned by company insiders.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.